Most people who catch Epstein-Barr virus get it from a kiss, feel terrible for a few weeks, and then carry it for life without knowing it. The virus settles quietly into the body, and for decades that was considered the end of the story. It is now looking less like an ending and more like a countdown.
Fred Hutch Cancer Center researchers have developed a monoclonal antibody — a single, targeted protein designed to latch onto and disable a specific part of a pathogen — that completely blocked EBV infection in humanized mice exposed to the virus. The finding, published in Cell Reports Medicine00035-2), represents the first time scientists have achieved full protection against EBV in a living animal model. One antibody, targeting a viral protein called gp42, prevented infection outright. A second antibody targeting a different viral protein, gp350, provided only partial protection. The research team, led by biochemist Andrew McGuire and pathobiology PhD student Crystal Chhan, identified ten antibodies in total before narrowing to the two most effective.
The stakes are not academic. EBV is one of the most successful human pathogens on record, establishing silent, lifelong infection in roughly 95% of the global population. It is best known as the cause of infectious mononucleosis, but its resume extends further: the National Institutes of Health has designated EBV a requisite risk factor for multiple sclerosis, meaning infection precedes the disease and dramatically raises its odds. EBV is also linked to several lymphomas, nasopharyngeal carcinoma, and gastric cancer. For the roughly 128,000 Americans who receive solid organ or bone marrow transplants each year, the virus poses a sharper problem. Immunosuppressive drugs given to prevent organ rejection leave these patients unable to control EBV if it reactivates, and there are currently no drugs specifically designed to prevent that.
Post-transplant lymphoproliferative disorder, an aggressive lymphoma driven by unchecked EBV infection, is a frequent cause of sickness and death after organ transplantation. Rachel Bender Ignacio, an infectious disease physician at Fred Hutch and the University of Washington, put it plainly: preventing EBV from spreading in these patients would reduce PTLD incidence, preserve graft function, and improve survival. She called effective prevention a significant unmet need in transplant medicine.
The difficulty has always been that EBV does not act like a typical virus. It infiltrates nearly every B cell in the body, which made blocking it at the entry point — the way neutralizing antibodies work against SARS-CoV-2 — look like trying to cork an ocean. The entry mechanism involves two viral proteins: gp350, which helps the virus grab onto human cells, and gp42, which mediates the fusion process that allows it inside. Most prior attempts focused on gp350 because it is abundant and easy to reach. The Fred Hutch team went after gp42 instead, betting that interrupting fusion would be more effective than blocking the initial attachment. The data bore that out. The gp42 antibodies performed categorically better, which the researchers say explains why the gp350-focused approach had stalled the field for years.
McGuire and Chhan used mice engineered to carry human antibody genes, a deliberate choice to avoid the anti-drug immune responses that commonly occur when patients receive antibodies derived from other animals. Fred Hutch has filed intellectual property covering the identified antibodies and is working with an undisclosed industry partner to move the research toward clinical development.
The MS connection is what makes the discovery commercially interesting beyond transplant medicine. If an antibody can prevent EBV from establishing infection in the first place, the logic extends to whether suppressing the virus after primary infection — before it seeds the hard-to-reach reservoirs where it persists — could reduce MS risk in people already infected. The NIH's position that EBV is a necessary precursor to MS does not prove that blocking EBV prevents MS, but it establishes the biological hypothesis that researchers and drug developers are now obligated to take seriously. The global market for MS disease-modifying therapies was worth roughly $25 billion in 2024 and is on track to reach $40 billion to $53 billion by the mid-2030s, according to industry analysts. That commercial landscape rests on the assumption that EBV is permanent. A prevention option would disrupt that assumption.
Whether the antibody can actually reach those compartments is the unresolved question. EBV operates in the central nervous system through infected B cells that cross the blood-brain barrier, and it is not yet clear whether peripheral antibody administration would suppress virus in those sanctuary sites sufficiently to alter the course of MS. Researchers have proposed EBV as a driver of MS for years without a prevention option to test the theory. This antibody is that option — in mice, at this stage. What it does not yet have is a development timeline, a named manufacturing partner, or a clear path to the MS indication. The transplant population is the nearer play: 128,000 patients a year in the US alone, no existing prophylactic, and a clearly defined regulatory pathway for a monoclonal antibody given as an infusion before or around the time of transplant.
The undisclosed industry partner is the part of this story that is not yet a story. Fred Hutch's press release and the paper itself are both silent on who is working with the lab to commercialize the antibody. For readers tracking where this goes next — whether that is a licensing deal, a spinout, or a pharma company quietly acquiring the IP — that is the thread worth pulling. The science is real. The need is documented. The partner will eventually have a name.
